Views & Analysis | Perspectives on pharma industry issues

Patients

Hands holding graphic representation of a kidney on a blue background

The forgotten few: Why the kidney transplant system is faili...

While innovation has reshaped therapeutic areas like oncology, transplant medicine has, by comparison, stood still.

Sales & Marketing

Agile learning focused on driving change: Lessons for Centre...

Less than 30% of digital transformations succeed across industries, while biopharma remains significantly behind (~20% succeed), with only a small minority of companies achieving scaled, en

Oncology

Bridging the cancer drug development gap: AI-driven precisio...

Functional precision oncology gives physicians the data they need to make better decisions about each patient’s care.

Patients

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.

Oncology

ASCO 2026: Are radiopharmaceuticals being systematically und...

The maximum dose of radiation prescribed by the FDA may be too conservative for novel therapies. But there's no easy solution to finding a new limit.

Views & Analysis

Livongo looks to set itself apart from digital health rivals

Paul Tunnah sat down with Livongo’s CEO Zane Burke to discuss how he has applied lessons from bigger companies in his new role and his thoughts on health tech’s relationship with patients a

Views & Analysis

Making real world evidence fit for purpose

Although real world evidence (RWE) is a hot topic in pharma right now, many still question whether it is acceptable to be used in regulatory decision making.

Views & Analysis

Doctor in the hand shows the scanning of the lung of the person.

The three biggest challenges in lung cancer, and how researc...

Despite new paradigm-shifting treatments, lung cancer remains a deadly disease – and improving outcomes requires more than just drug research.

Sales & Marketing

Agile learning focused on driving change: Lessons for Centre...

Less than 30% of digital transformations succeed across industries, while biopharma remains significantly behind (~20% succeed), with only a small minority of companies achieving scaled, en

Sales & Marketing

Are pharma teams ready for the next customer engagement mode...

The infrastructure is largely in place.

Digital

The pulse of progress: AI, real-world data, and the ethics o...

What kind of data should train and power the next generation of healthcare AI?

Digital

The future of feasibility: AI-driven site selection & protoc...

AI can help sponsors identify higher-potential sites, improve enrolment predictability, and accelerate study startup timelines.

Market Access

Industry exercises option for midpoint review of VPAG Invest...

Under the VPAG agreement, £400 million is available under the VPAG Investment Fund. But what benefits will stay once funding goes away in 2029?

Market Access

Approval designed from day one: Building global-ready regula...

The global pharmaceutical landscape is increasingly defined by the necessity for clinical acceleration without compromising data integrity.

Oncology

Bridging the cancer drug development gap: AI-driven precisio...

Functional precision oncology gives physicians the data they need to make better decisions about each patient’s care.

Oncology

ASCO 2026: Are radiopharmaceuticals being systematically und...

The maximum dose of radiation prescribed by the FDA may be too conservative for novel therapies. But there's no easy solution to finding a new limit.

Oncology

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.